As of 2026-01-16, the EV/EBITDA ratio of Travere Therapeutics Inc (TVTX) is -71.04. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TVTX's latest enterprise value is 2,493.53 mil USD. TVTX's TTM EBITDA according to its financial statements is -35.10 mil USD. Dividing these 2 quantities gives us the above TVTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.0x - 15.4x | 14.4x |
| Forward P/E multiples | 15.6x - 20.4x | 17.8x |
| Fair Price | (6.14) - (6.03) | (6.32) |
| Upside | -122.0% - -121.6% | -122.7% |
| Date | EV/EBITDA |